Citations

Background: Polyetheretherketone (PEEK) is a commonly used material for cranioplasties due to its advantages over other materials and autologous bone grafts. PEEK has an increased malleability, which increases postoperative aesthetics and adapts well to the cranial contours; it is also associated with a lower rate of infection when compared with autologous cranioplasties. Despite these benefits, there is limited information on the practical aspects of modifying PEEK cranioplasties after their initial placement. Case Series: We present 2 cases of patients who had previously undergone PEEK cranioplasty being treated with deep-brain stimulation (DBS), which was placed through their PEEK implant. The first was an 18-year-old male who had previously undergone cranial vault closure with bone grafts following a craniotomy. Later, when a deep-brain stimulator was planned, it was discovered that the bone grafts had significant resorption and a lack of structural integrity. Therefore, bone grafts were replaced with a custom PEEK implant cranioplasty before the DBS electrodes were placed via drilling through the PEEK implant to access the brain at a later surgery. The second patient was a 39-year-old male who developed epilepsy after a stroke, requiring craniotomy. DBS was unable to be performed initially due to significant resorption of the patient’s native bone. Therefore, a PEEK cranioplasty was performed in preparation for a staged, subsequent placement of DBS electrodes through the implant. Both patients recovered uneventfully following surgery, with noticeable improvement in functional (reduction in seizure frequency) and aesthetic outcomes. Systematic Review: A literature review was conducted using PubMed with keywords related to PEEK cranioplasties. After screening titles, abstracts, and full-text papers, it was found that 3 previously documented cases have involved drilling through PEEK implants: one by Mallela et al, involving SEEG electrode placement; one by Marrone et al, concerning a burr hole for evacuating a chronic subdural hematoma; and one by Ledesma et al, regarding the placement of subdural grid electrodes. Conclusions: This case series highlights how PEEK cranioplasties can be drilled through for therapeutic procedures, such as DBS electrode implantation, without compromising their structure. These cases illustrate the versatility, safety, and adaptability of PEEK implants for additional necessary interventions.

Wearable inertial measurement units (IMUs) offer an accessible alternative to optical motion capture (MoCap) gait analysis, but their performance in Progressive Supranuclear Palsy (PSP) requires validation. We assessed the concurrent validity of IMU-derived versus MoCap-derived gait metrics and static postural sway in 30 patients with PSP using Bland–Altman analysis, Intraclass Correlation Coefficients (ICC), and Spearman rank correlations. Finally, we assessed equivalence using the Two one-sided tests (TOST) procedure. Multivariable linear regression was used to determine whether clinical severity, as measured by the PSP Rating Scale (PSPRS), independently predicted absolute IMU measurement error while controlling for patient age and gait velocity. IMUs demonstrated excellent between-system agreement for parameters such as cadence (100.76 ± 11.42 vs. 100.52 ± 11.59) and cycle time (1.21 ± 0.15 vs. 1.22 ± 0.15; ICC > 0.98), despite a systematic underestimation of gait velocity (p < 0.05). Agreement significantly diminished for micro-phases (e.g., single/double support times) and spatial asymmetry. Interestingly, the TOST procedure revealed that only sagittal and transverse trunk kinematics were equivalent between systems, with all other measures failing to find equivalency. For static sway, the IMU demonstrated strong rank-order correspondence for tracking relative postural instability (ρ = 0.82, p < 0.05). Multivariable analysis revealed that higher PSPRS scores are independently associated with greater between-system discrepancies in support phases and pelvic and trunk kinematics (p < 0.05), irrespective of reduced gait speed. These findings highlight the need to develop disease-specific algorithms, rather than relying on normative commercial models, to establish reliable digital biomarkers for monitoring progressive motor decline.

ABSTRACT Many real‐world patients with advanced biliary tract cancer (BTC) are excluded by TOPAZ‐1 criteria; this study assessed cisplatin and gemcitabine plus durvalumab (CGD) efficacy and safety in these patients. Data from 1358 patients with advanced BTC treated with first‐line CGD across 55 international centers were retrospectively analyzed. Patients were classified as TOPAZ‐1‐in (meeting all inclusion criteria) or TOPAZ‐1‐out (meeting ≥ 1 exclusion criterion). Primary endpoints were overall survival (OS) and progression‐free survival (PFS); secondary endpoints included objective response rate (ORR), disease control rate (DCR), and safety. Furthermore, OS and PFS of the TOPAZ‐1‐out cohort were compared with reconstructed survival data from the phase III trial. 912 (67.1%) patients were classified as TOPAZ‐1‐in , and 446 (32.9%) as TOPAZ‐1‐out . After a median follow‐up of 14.5 months (95% CI: 13.7–36.5), OS was 16.1 months in TOPAZ‐1‐in and 12.5 months in TOPAZ‐1‐out (HR 0.69, 95% CI: 14.6–16.5, p = 0.0001); PFS was 8.2 versus 6.5 months (HR 0.73, 95% CI: 7.1–8.1, p < 0.0001). Median OS in the TOPAZ‐1‐out cohort (12.5 months) was nearly identical to the phase III trial experimental arm (12.9 months; HR 1.15, p = 0.13); for PFS the HR was 1.12 (95% CI 0.93–1.42; p = 0.09). Among TOPAZ‐1‐out patients, active infection, elevated bilirubin, and ECOG PS > 1 were linked to poorer OS, while no detrimental impact emerged for ALT/AST abnormalities, corticosteroid use, renal or hematologic parameters, or prior surgery within 6 months, suggesting treatment effectiveness was broadly maintained across clinical subgroups. Furthermore, TOPAZ‐1‐out patients experienced no significant increase in adverse events compared with the TOPAZ‐1‐in group. Real‐world data suggest CGD may be effective in TOPAZ‐1‐out patients, with no evident increase in toxicity, supporting the potential expanded use of the regimen in clinical practice.

Craniosynostosis is a congenital disorder characterized by premature fusion of cranial sutures. Lambdoid synostosis is a rare and severe form of the disease, but its developmental etiology remains poorly understood. Although ectopic cartilage has been associated with lambdoid suture fusion, whether abnormal chondrocyte development is causative has not been directly tested. Here, we investigated the role of platelet-derived growth factor receptor alpha (PDGFRα) signaling in chondrocyte development and lambdoid suture morphogenesis. Mesoderm-specific expression of an autoactivated Pdgfra allele (Pdgfra+/K) caused premature fusion of the lambdoid and occipitointerparietal sutures, preceded by excessive cartilage expansion during embryogenesis. Spatial transcriptomic analysis identified a PDGFRα-dependent transcriptional program characterized by increased Col2a1, Sox9, and Sfrp2 expression, indicating maintenance of chondrocytes in a proliferative progenitor state. Consistently, PDGFRα-activated chondrocytes exhibited increased proliferation. Moreover, expression of Pdgfra+/K in the Col2a1Cre lineage selectively induced occipitointerparietal suture fusion. Together, these findings demonstrate that PDGFRα signaling promotes proliferative cartilage and impairs chondrocyte maturation, identifying dysregulated chondrogenesis as a developmental mechanism underlying lambdoid craniosynostosis.

Background Premature and early menopause involve ovarian hormone deprivation, which may contribute to later-life vulnerability to cognitive decline and neurodegenerative diseases. Multimodal neuroimaging biomarkers provide a means of detecting structural, microstructural, functional, and molecular brain changes before clinical symptoms emerge. Methods Following PRISMA guidelines, we conducted a systematic search of PubMed. Study quality was assessed using the Newcastle–Ottawa Scale. Results Neuroimaging modalities included in vivo structural magnetic resonance imaging (MRI) ( n = 16), functional MRI ( n = 2), diffusion tensor imaging ( n = 4), and positron emission tomography ( n = 3). Women with premature or early menopause showed regionally specific structural and microstructural brain abnormalities, including lower gray-matter volume or cortical thickness in medial temporal, frontal, and basal forebrain regions; white-matter microstructural abnormalities in the anterior corona radiata, corpus callosum, and fronto-occipital tracts; and reduced posterior hippocampal activation during memory encoding. In one study, earlier age at menopause was associated with higher amyloid- β (Aβ) burden in women who underwent premenopausal bilateral oophorectomy (PBO), and elevated tau deposition was reported predominantly among women with higher Aβ levels. Conclusion Converging multimodal neuroimaging evidence suggests that premature and early menopause may be associated with Alzheimer’s disease-relevant brain changes. However, findings remain heterogeneous, and longitudinal studies are needed to clarify the temporal relationships between ovarian hormone deprivation and neurodegeneration, and to determine the clinical implication of these findings.

Abstract: Background Artificial intelligence (AI)-assisted colonoscopy reduces costs in colorectal cancer screening, but its incremental value relative to non-AI resect-and-discard (RD) strategies for diminutive polyps (≤ 5 mm) remain unclear. We aimed to compare the clinical, economic, and environmental outcomes of AI-assisted and non-AI RD strategies with standard of care (SoC). Methods In our Markov model simulating 6 million individuals aged ≥45 years undergoing screening colonoscopy, 4 strategies were evaluated: SoC, non-AI RD, CADe-assisted RD (CADe-RD), and CADe+CADx-assisted RD (CADe+CADx-RD). The primary outcome was total quality-adjusted life years (QALYs), with secondary outcomes including cost and carbon dioxide (CO₂) emissions. Results Non-AI RD achieved the lowest total cost ($36.6B) and carbon emissions (0.90 million kg CO₂), while yielding the highest QALYs (51.37 million), although differences in QALYs across strategies were small (<0.01%). CADe-RD and CADe+CADx-RD remained cost-saving relative to SoC ($36.9B and $37.4B vs $37.8B, respectively) but were associated with higher costs than non-AI RD. CADe modestly increased adenoma detection without improving QALYs, while the addition of CADx increased costs and emissions and resulted in slightly lower QALYs. Sensitivity analysis showed that CADe+CADx-RD matched or exceeded CADe-RD QALYs only within a limited region of high diagnostic performance. At currently reported CADx performance levels, CADe+CADx-RD yielded lower QALYs and higher costs than CADe-RD. CADe+CADx-RD achieved non-inferiority in QALYs relative to CADe-RD only within a limited region of high diagnostic performance. Conclusions In our non-deterministic model, non-AI RD provided the optimal balance of clinical benefit, cost savings, and lowest environmental impact.